In addition, the phase 2 NCT01925612 trial explored the first‐line application of BV in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHP) for high‐intermediate/high‐risk DLBCL patients, and the results showed an ORR of 91%, while for CD30+ patients, the 18‐month PFS rate was 79% and the OS rate was 92%.111. Here, TNFRSF8 is linked to diffuse large B-cell lymphoma.